Skip to main content
RAPT Therapeutics, Inc. logo

RAPT Therapeutics, Inc. — Investor Relations & Filings

Ticker · RAPT ISIN · US75382E1091 LEI · 549300MB473BIU78ES48 US Manufacturing
Filings indexed 534 across all filing types
Latest filing 2021-12-06 Director's Dealing
Country US United States of America
Listing US RAPT

About RAPT Therapeutics, Inc.

https://rapt.com/

RAPT Therapeutics, Inc. is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients with inflammatory and immunologic diseases. The company's scientific approach involves developing therapeutics that intelligently target key drivers of the immune system. Its pipeline includes ozureprubart (RPT904), a long-acting anti-IgE antibody being evaluated in a Phase 2b clinical trial for the treatment of food allergies.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2021-12-06 English
FORM 4 SUBMISSION
Director's Dealing
2021-11-11 English
FORM 3 SUBMISSION
Director's Dealing
2021-11-11 English
RAPT-Q3-20210930
Interim / Quarterly Report Q3 2021
2021-11-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text includes an Item 2.02 section reporting the company's third quarter financial results via a press release, but the financial results themselves are not included in the document, only the announcement of the press release. Additionally, Item 5.02 announces the appointment of a new board member and related details. The document does not contain full financial statements or detailed financial analysis, only a summary and announcement of events. Therefore, it is not an Interim/Quarterly Report (IR) or Annual Report (10-K), but rather a Regulatory Filing (RNS) reporting material corporate events and referencing a press release. The document length (6892 characters) is moderate but the content is primarily announcements and not the full report itself.
2021-11-10 English
PRIMARY DOCUMENT
Director's Dealing
2021-10-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.